146 related articles for article (PubMed ID: 37810973)
41. Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study.
Zhou J; Qin H; Miao J; Liu R; Wang W
Medicine (Baltimore); 2023 Jun; 102(26):e34110. PubMed ID: 37390279
[TBL] [Abstract][Full Text] [Related]
42. Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study.
Song L; Zhou F; Xu T; Zeng L; Xia Q; Wang Z; Deng L; Li Y; Qin H; Yan H; Huang Z; Mi J; Xu Q; Yang N; Zhou C; Zhang Y
BMC Cancer; 2023 May; 23(1):443. PubMed ID: 37189075
[TBL] [Abstract][Full Text] [Related]
43. The Impact of Poorly Differentiated Histology on Immunotherapy in Advanced Gastrointestinal Cancers.
Draper A; Jung EH; Cao Y; Atallah RP; Switchenko J; Kane S; Guadagno J; Jones AT; Brutcher E; Alese OB
Oncology; 2023; 101(4):213-223. PubMed ID: 36626879
[TBL] [Abstract][Full Text] [Related]
44. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129
[TBL] [Abstract][Full Text] [Related]
45. Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology.
Boscolo Bielo L; Belli C; Crimini E; Repetto M; Ascione L; Pellizzari G; Santoro C; Fuorivia V; Barberis M; Fusco N; Rocco EG; Curigliano G
Oncologist; 2024 Jun; 29(6):504-510. PubMed ID: 38520742
[TBL] [Abstract][Full Text] [Related]
46. Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancer.
Zheng Q; Wu C; Ye H; Xu Z; Ji Y; Rao J; Lu L; Zhu Y; Cheng F
Ann Transl Med; 2021 Oct; 9(20):1568. PubMed ID: 34790774
[TBL] [Abstract][Full Text] [Related]
47. Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study.
Jiang M; Shao B; Wan D; Liu J; He M; Chai Y; Sang D; Wang J; Ma F; Fan Y; Yuan P; Xu B; Li Q
Ther Adv Med Oncol; 2023; 15():17588359231204856. PubMed ID: 37841751
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies.
Gao RL; Song J; Sun L; Wu ZX; Yi XF; Zhang SL; Huang LT; Ma JT; Han CB
Front Pharmacol; 2022; 13():920165. PubMed ID: 36034821
[No Abstract] [Full Text] [Related]
49. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
Metaxas Y; Früh M; Eboulet EI; Grosso F; Pless M; Zucali PA; Ceresoli GL; Mark M; Schneider M; Maconi A; Perrino M; Biaggi-Rudolf C; Froesch P; Schmid S; Waibel C; Appenzeller C; Rauch D; von Moos R;
Ann Oncol; 2020 Apr; 31(4):495-500. PubMed ID: 32085891
[TBL] [Abstract][Full Text] [Related]
50. Survival Outcomes Associated with First and Second-Line Palliative Systemic Therapies in Patients with Metastatic Bladder Cancer.
Beigi A; Vafaei-Nodeh S; Huang L; Sun SZ; Ko JJ
Curr Oncol; 2021 Sep; 28(5):3812-3824. PubMed ID: 34677243
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study.
Yin S; Chi Y; Du Y; Wang J; Shan C; Yi W; Shang M; Man X; Tan Q; Li H
Cancer Med; 2023 Feb; 12(3):2333-2344. PubMed ID: 35894763
[TBL] [Abstract][Full Text] [Related]
52. Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis.
Huang M; Li J; Yu X; Xu Q; Zhang X; Dai X; Li S; Sheng L; Huang K; Liu L
Front Oncol; 2021; 11():734323. PubMed ID: 34745955
[TBL] [Abstract][Full Text] [Related]
53. Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy Protocols.
Roehrle J; Kasper S; Treckmann JW; Markus P; Schumacher B; Albers D; Wendling J; Ting S; Mende B; Maßmann M; Markus M; Virchow I; Rosery V; Laue K; Zaun G; Kostbade K; Pogorzelski M; Reissig TM; Liffers ST; Schmid K; Schildhaus HU; Schuler M; Siveke JT; Wiesweg M
Oncol Res Treat; 2023; 46(4):140-150. PubMed ID: 36720216
[TBL] [Abstract][Full Text] [Related]
54. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).
Park HS; Kang B; Chon HJ; Im HS; Lee CK; Kim I; Kang MJ; Hwang JE; Bae WK; Cheon J; Park JO; Hong JY; Kang JH; Kim JH; Lim SH; Kim JW; Kim JW; Yoo C; Choi HJ
ESMO Open; 2021 Apr; 6(2):100049. PubMed ID: 33578192
[TBL] [Abstract][Full Text] [Related]
55. A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy.
Weinberg BA; Wang H; Witkiewicz AK; Marshall JL; He AR; Vail P; Knudsen ES; Pishvaian MJ
J Pancreat Cancer; 2020; 6(1):45-54. PubMed ID: 32642630
[No Abstract] [Full Text] [Related]
56. [Efficacy and safety evaluation of immunotherapy combined with targeted therapy as second-line treatment in patients with metastatic non-clear cell renal cell carcinoma].
Wang J; Wei WS; Jiang LJ; Zhang ZL; Guo SJ; Han H; Zhou FJ; Dong P
Zhonghua Zhong Liu Za Zhi; 2023 Aug; 45(8):704-708. PubMed ID: 37580277
[No Abstract] [Full Text] [Related]
57. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
[TBL] [Abstract][Full Text] [Related]
58. FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer.
Catalano M; Conca R; Petrioli R; Ramello M; Roviello G
Cancer Manag Res; 2020; 12():10271-10278. PubMed ID: 33116881
[TBL] [Abstract][Full Text] [Related]
59. Chemotherapy Combined With Recombinant Human Endostatin (Endostar) Significantly Improves the Progression-Free Survival of Stage IV Soft Tissue Sarcomas.
Liao Z; Zhang C; Yang T; Liu H; Yang S; Li T; Xing R; Teng S; Yang Y; Zhao J; Zhao G; Bai X; Zhu L; Yang J
Front Oncol; 2021; 11():778774. PubMed ID: 35047396
[TBL] [Abstract][Full Text] [Related]
60. Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.
Smyth EN; Bapat B; Ball DE; André T; Kaye JA
Clin Ther; 2015 Jun; 37(6):1301-16. PubMed ID: 25907619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
